Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Tenecteplasa para accidente cerebrovascular en ventana tardía guiado por discordancia DWI-FLAIR (TRUST-MISMATCH)

5 de noviembre de 2026 actualizado por: Bo Song, The First Affiliated Hospital of Zhengzhou University

Tenecteplasa para la trombólisis en el accidente cerebrovascular isquémico agudo en la ventana de 4,5 a 9 horas guiada por discordancia DWI-FLAIR: un ensayo multicéntrico, prospectivo, aleatorizado, doble ciego y controlado con placebo

The goal of this clinical trial is to evaluate the efficacy and safety of tenecteplase administered 4.5-9 hours after stroke onset (defined as the time the patient was first found with symptoms, including wake-up stroke and unwitnessed stroke) in patients with acute ischemic stroke (AIS) guided by DWI-FLAIR mismatch on MRI. The main questions it aims to answer are:

  1. Does tenecteplase improve functional outcomes at 90 days compared with standard treatments in AIS patients administered 4.5-9 hours after stroke onset guided by DWI-FLAIR mismatch?
  2. The safety of tenecteplase thrombolysis for AIS patients in the 4.5-9 hours guided by DWI-FLAIR mismatch.

Researchers will compare tenecteplase to placebo to see if it is effective and safe for these patients.

Participants will be randomly assigned (1:1) immediately after randomization:

  • Tenecteplase group: received tenecteplase, intravenously as a bolus administered over a period of 5 to 10 seconds at a dose of 0.25 mg per kilogram (maximum dose, 25 mg), plus aspirin placebo (300 mg).
  • Control group: aspirin (300 mg) plus tenecteplase placebo. From day 2 to day 90, all patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Current clinical guidelines recommend intravenous thrombolysis (IVT) for eligible AIS patients within 4.5 hours of symptom onset. However, approximately 67 to 75% of patients present after 4.5 hours after stroke onset or with an unknown time of onset. CT perfusion (CTP) and perfusion-diffusion magnetic resonance imaging (MRI) have demonstrated that potentially viable brain tissue may persist beyond 4.5 hours after stroke onset. Recent trials, such as EXTEND, TRACE III, and the HOPE study, suggest that IVT can improve functional outcomes in AIS patients with salvageable brain tissue identified beyond 4.5 hours and up to 24 hours, using advanced perfusion imaging. Nonetheless, due to the high cost of perfusion software in developing countries, extended-window thrombolysis has not been widely implemented in many stroke centers. Therefore, it is crucial to develop alternative strategies to guide IVT in patients beyond 4.5 hours.

In recent years, the mismatch between a visible acute ischemic lesion on diffusion-weighted imaging (DWI) and the absence of a corresponding hyperintensity on fluid-attenuated inversion recovery (FLAIR) has been recognized as a predictor of symptom onset within 4.5 hours before imaging. The WAKE-UP trial demonstrated that among AIS patients with unknown time of onset (last known well >4.5 hours) and DWI-FLAIR mismatch, IVT administered within 4.5 hours after symptom recognition significantly improved functional outcomes. However, approximately 30% of AIS patients exhibit DWI-FLAIR mismatch between 4.5 and 9 hours after onset. Whether these patients can benefit from thrombolysis remains uncertain.

TRUST-MISMATCH is a multicenter, prospective, randomized, double-blind, placebo-controlled clinical. We want to evaluate the efficacy and safety of tenecteplase administered 4.5-9 hours after stroke onset (defined as the time the patient was first found with symptoms, including wake-up stroke and unwitnessed stroke) in AIS patients guided by DWI-FLAIR mismatch on MRI.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

564

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Bo Song, MD
  • Número de teléfono: +86-371-66278068
  • Correo electrónico: fccsongb@zzu.edu.cn

Ubicaciones de estudio

    • Henan
      • Zhengzhou, Henan, Porcelana, 450052
        • Reclutamiento
        • The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Age ≥ 18 years;

  2. AIS with symptom onset 4.5-9 hours before enrollment, including wake-up stroke and unwitnessed stroke (onset time defined as when symptoms were first noticed);

  3. Imaging criteria:

    1. DWI-FLAIR mismatch: visible lesion on DWI with no marked visible lesion on FLAIR;
    2. DWI infarct core not exceeding one-third of the middle cerebral artery territory, one-half of the anterior cerebral artery territory, or one-half of the posterior cerebral artery territory;
  4. NIHSS score 4-25;

  5. First-ever stroke or previous stroke without significant disability (pre-stroke mRS ≤ 1);

  6. Signed informed consent from the patient or legally authorized representative.

Exclusion Criteria:

  1. Planned endovascular treatment;
  2. Contradictory to MRI examination;
  3. MRI image not qualified for evaluation;
  4. Obvious head injuries or strokes within 3 months;
  5. Subarachnoid or intracranial hemorrhage;
  6. History of intracranial hemorrhage;
  7. Intracranial tumor, arteriovenous malformation or aneurysm;
  8. Intracranial or spinal cord surgery within 3 months;
  9. Active internal hemorrhage;
  10. platelet count of <100000/mm3;
  11. Aortic arch dissection;
  12. Heparin therapy within 24 hours;
  13. Oral warfarin is being taken and INR>1.6 or APTT abnormal;
  14. Oral anticoagulation therapy;
  15. Systolic pressure≥185 mmHg or diastolic pressure≥110 mmHg;
  16. Blood glucose < 50 mg/dl (2.7mmol/L);
  17. Pregnancy;
  18. Neurological deficit after epileptic seizures;
  19. Major surgery within 1 month;
  20. Gastrointestinal or urinary tract hemorrhage within the previous 30 days;
  21. Myocardial infarction within 3 months;
  22. Allergy to study drugs;
  23. Unlikely to adhere to the trial protocol or follow-up;
  24. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;
  25. Participation in other interventional clinical trials within the previous 3 months.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Tenecteplase group:

Patients will receive tenecteplase, intravenously as a bolus administered over a period of 5 to 10 seconds at a dose of 0.25 mg per kilogram (maximum dose, 25 mg), plus aspirin placebo (300 mg) immediately after randomization.From day 2 to day 90, all patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.

TNK-tPA (0.25 mg/kg, to maximum of 25mg)

Asprin (placebo)

TNK-tPA (placebo)

Comparador activo: Control group

Patients will receive asprin(300mg) plus intravenous TNK(placebo, 0.25mg/kg, a maximum of 25 mg) immediately after randomization. From day 2 to day 90, patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.

Asprin (placebo)

TNK-tPA (placebo)

Asprin (300mg)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Modified Rankin Scale (mRS)
Periodo de tiempo: 90 ± 7 days

Proportion of subjects of excellent outcome defined as mRS (0-1) at 90 ± 7 days.

90 ± 7 days

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Modified Rankin Scale (mRS)
Periodo de tiempo: 90 ± 7 days

Proportion of subjects of excellent outcome defined as mRS (0-2) at 90 ± 7 days.

90 ± 7 days
Modified Rankin Scale (mRS)
Periodo de tiempo: 90 days

Ordinal shift analysis of mRS at 90 days

90 days
National Institutes of Health Stroke Scale (NIHSS)
Periodo de tiempo: 72 hours and 7 ± 1 days (or at discharge)

Proportion of subjects with an improvement in NIHSS score of ≥2 points from baseline.

72 hours and 7 ± 1 days (or at discharge)
National Institutes of Health Stroke Scale (NIHSS)
Periodo de tiempo: 72 hours and 7 ± 1 days (or at discharge)

Proportion of subjects achieving an NIHSS score of ≤1.

72 hours and 7 ± 1 days (or at discharge)
Barthel (BI)
Periodo de tiempo: 90 ± 7 days

Barthel Index score at 90 ± 7 days.

90 ± 7 days
EuroQol 5-Dimension (EQ-5D)
Periodo de tiempo: 90 ± 7 days

Quality of life measured by EQ-5D scale at 90 ± 7 days.

90 ± 7 days
Modified Rankin Scale (mRS)
Periodo de tiempo: 90 ± 7 days
  1. Proportion of subjects of excellent outcome defined as mRS (0-2) at 90 ± 7 days.
  2. Ordinal distribution of mRS at 90 ± 7 days
90 ± 7 days

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Symptomatic intracranial hemorrhage (sICH)
Periodo de tiempo: 36 hours

Proportion of subjects with symptomatic intracranial hemorrhage (sICH) within 36 hours (according to the ECASS III criteria for the primary safety analysis, with SITS-MOST and Heidelberg definitions used for supportive analyses).

36 hours
Death
Periodo de tiempo: 90 days

Overall mortality rate at 90 days.

90 days
Systemic bleeding
Periodo de tiempo: 90 days

Systemic bleeding at 90 days (according to the GUSTO criteria)

90 days
Adverse events (AEs)/ serious adverse events (SAEs)
Periodo de tiempo: 90 ± 7 days

Proportion of patients with adverse events (AEs)/ serious adverse events (SAEs) within 90 ± 7 days.

90 ± 7 days
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Periodo de tiempo: 90 ± 7 days

Proportion of subjects experiencing MACCE (defined as ischemic stroke, hemorrhagic stroke, transient ischemic attack, myocardial infarction, or vascular death).

90 ± 7 days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Silla de estudio: Bo Song, MD, Department of Neurology, the First Affiliated Hospital of Zhengzhou University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

2 de noviembre de 2026

Finalización primaria (Estimado)

29 de febrero de 2028

Finalización del estudio (Estimado)

31 de octubre de 2028

Fechas de registro del estudio

Enviado por primera vez

6 de abril de 2026

Primero enviado que cumplió con los criterios de control de calidad

17 de abril de 2026

Publicado por primera vez (Actual)

20 de abril de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • MISMATCH-001

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .